Karyopharm Therapeutics (NASDAQ: KPTI) reported Q4 EPS of ($0.36), $0.05 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $33.7 million versus the consensus estimate of $35.57 million.

GUIDANCE:

Karyopharm Therapeutics sees FY2024 revenue of $140-160 million, versus the consensus of $157.9 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.